Klimai Medicine

Clearmind Medicine is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, non-hallucinogenic, psychedelic-derived neuroplastogens to treat widespread and underserved health problems, including alcohol use disorder (AUD), binge drinking, eating disorders, and other mental health and metabolic conditions. The company's lead investigational candidate, CMND-100 (an oral formulation of MEAI, or 5-methoxy-2-aminoindane), is currently in Phase I/IIa clinical trials for AUD, designed to promote adaptive neuroplasticity and reduce alcohol cravings without inducing hallucinogenic effects. Clearmind is also advancing a robust pipeline of other psychoactive compounds and combination therapies, including 2-fluorodeschloroketamine (2-FDCK) for depression, and combinations of psychedelics (such as MDMA, LSD, ketamine, and ibogaine) with palmitoylethanolamide (PEA) to enhance therapeutic potency and safety. Headquartered in Vancouver, Canada, with research operations in Israel, the company leverages strategic collaborations with academic and industry partners to build a strong global intellectual property portfolio.